Cargando…

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease

Patient: Female, 44 Final Diagnosis: Deterioration of renal and heart function Symptoms: Hypercalcemia Medication: — Clinical Procedure: Laboratory Specialty: Nephrology OBJECTIVE: Rare disease BACKGROUND: Fabry disease is a rare and progressive X-linked inherited disorder of glycosphingolipid metab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keber, Tajda, Tretjak, Martin, Vujkovac, Andreja Cokan, Mravljak, Marija, Ravber, Katja, Vujkovac, Bojan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471926/ https://www.ncbi.nlm.nih.gov/pubmed/28596512 http://dx.doi.org/10.12659/AJCR.903886

Ejemplares similares

Podocyturia in Fabry disease: a 10-year follow-up
por: Vujkovac, Bojan, et al.
Publicado: (2021)

Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy
por: Levstek, Tina, et al.
Publicado: (2023)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

Polymorphisms of the PPAR-γ (rs1801282) and Its Coactivator (rs8192673) Have a Minor Effect on Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
por: Pleskovič, Aleš, et al.
Publicado: (2016)

Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy
por: Levstek, Tina, et al.
Publicado: (2021)

Vascular Endothelial Growth Factor Gene Polymorphism (rs2010963) and Its Receptor, Kinase Insert Domain-Containing Receptor Gene Polymorphism (rs2071559), and Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
por: Merlo, Sebastjan, et al.
Publicado: (2016)

Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR
por: Trimarchi, H., et al.
Publicado: (2014)

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
por: De Nicola, Luca, et al.
Publicado: (2012)

Polymorphism rs5498 of the ICAM-1 gene affects the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus
por: Popović, Dražen, et al.
Publicado: (2016)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

Evaluation of antiproteinuric and hepato-renal protective activities of propolis in paracetamol toxicity in rats
por: El Menyiy, Nawal, et al.
Publicado: (2018)

PECAM-1 gene polymorphism (rs668) and subclinical markers of carotid atherosclerosis in patients with type 2 diabetes mellitus
por: Popović, D, et al.
Publicado: (2016)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Is the Antiproteinuric Effect of Cyclosporine A Independent of Its Immunosuppressive Function in T Cells?
por: Zhang, Bin, et al.
Publicado: (2012)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Type 1 Kounis Syndrome in Patient with Idiopathic Anaphylaxis
por: Keber, Tajda, et al.
Publicado: (2017)

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
por: Ritter, Cynthia, et al.
Publicado: (2014)

Effect of systemic arterial hypertension and use of antiproteinuric drug in induction therapy for lupus nephritis
por: Matta, Eduardo Grecco, et al.
Publicado: (2020)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Association of the ACE rs4646994 and rs4341 polymorphisms with the progression of carotid atherosclerosis in slovenian patients with type 2 diabetes mellitus
por: Merlo, S, et al.
Publicado: (2016)

Role of the eNOS-NO System in Regulating the Antiproteinuric Effects of VEGF Receptor 2 Inhibition in Diabetes
por: Advani, Andrew, et al.
Publicado: (2013)

Antiproteinuric and Hyperkalemic Mechanisms Activated by Dual Versus Single Blockade of the RAS in Renovascular Hypertensive Rats
por: Corrêa, José Wilson N., et al.
Publicado: (2021)

Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease
por: Capelli, Irene, et al.
Publicado: (2023)

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
por: Pihlstrøm, Hege Kampen, et al.
Publicado: (2020)

The Protective Potential of Petroselinum crispum (Mill.) Fuss. on Paracetamol-Induced Hepatio-Renal Toxicity and Antiproteinuric Effect: A Biochemical, Hematological, and Histopathological Study
por: Nouioura, Ghizlane, et al.
Publicado: (2023)

Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD
por: Wouda, Rosa D, et al.
Publicado: (2021)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Anti-inflammatory and anti-apoptotic effects of paricalcitol in lipopolysaccharide-induced renal proximal tubular cell injury
por: Kim, Soo Wan
Publicado: (2017)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7lmqolbs9eredf96eacejfvj45